Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Editas Medicine, Inc. (EDIT)
USD3.02
-0.15 (-4.59%)
US NASDAQ Healthcare Biotechnology
Address
11 Hurley Street 2141
Cambridge, MA, US
Cambridge, MA, US
CEO
Gilmore O'Neill
Website
editasmedicine.com
IPO
2016-02-03
CIK 1650664 ISIN US28106W1036
Also trades on
London Stock Exchange · 0IFK.L (USD)
NASDAQ Global Select · EDIT (USD)
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.02
-0.15 (-4.59%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
2.10
Float Shares
97.45M
Free Float %
99.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.87% | +40.65% | +15.33% | +57.27% | +43.57% | +68.78% | +101.16% | -61.38% | -89.89% | -90.67% | -80.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (25 ratings, all time)
Buy
Price Targets & DCF
Current price
3.02
Low
4.00
+32.7%
Consensus
5.00
+65.8%
Median
5.00
+65.8%
High
6.00
+99.0%
Ratings Trend (MoM)
54% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 7 | 0 |
| Hold | 4 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 2 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
4.00
+32.7%
|
| Last Quarter | 2 |
5.00
+65.8%
|
| Last Year | 2 |
5.00
+65.8%
|
| All Time | 20 |
18.40
+510.3%
|
Quality scores
Altman Z-Score
-15.45
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+25.4% ★ Q1'26: -39.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+37.5% ★ Q1'26: +71.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-460.6% Q1'26: -817.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-379.8% Q1'26: -883.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +211.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+7.8% Q1'26: +17.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.52× Q1'26: -0.73× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 8 EPS Ana. |
Dec 2027 8 Rev. Ana. 7 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.63M
est: 1.29M (+26.4%)
|
6.05M
est: 6.65M (-9.0%)
|
13.73M
est: 14.67M (-6.4%)
|
31.94M
est: 46.43M (-31.2%)
|
20.53M
est: 56.06M (-63.4%)
|
90.73M
est: 85.15M (+6.6%)
|
25.54M
est: 17.41M (+46.8%)
|
19.71M
est: 16.59M (+18.8%)
|
78.12M
est: 67.03M (+16.5%)
|
32.31M
est: 34.36M (-5.9%)
|
40.52M
est: 24.14M (+67.9%)
|
14.80M
10.32M – 21.96M
-38.7% YoY
|
13.48M
11.40M – 17.38M
-8.9% YoY
|
7.57M
4.06M – 13.51M
-43.8% YoY
|
8.54M
4.58M – 15.23M
+12.8% YoY
|
17.25M
9.25M – 30.76M
+102.0% YoY
|
| EBITDA |
-72.29M
est: -1.29M (-5,508.5%)
|
-96.07M
est: -6.65M (-1,344.5%)
|
-116.66M
est: -14.67M (-695.1%)
|
-110.47M
est: -97.78M (-13.0%)
|
-138.09M
est: -286.32M (+51.8%)
|
-130.88M
est: -96.35M (-35.8%)
|
-188.09M
est: -197.75M (+4.9%)
|
-219.61M
est: -162.49M (-35.2%)
|
-163.12M
est: -67.03M (-143.3%)
|
-233.11M
est: -34.36M (-578.5%)
|
-148.61M
est: -24.14M (-515.8%)
|
-14.80M
-21.96M – -10.32M
+38.7% YoY
|
-13.48M
-17.38M – -11.40M
+8.9% YoY
|
-7.57M
-13.51M – -4.06M
+43.8% YoY
|
-8.54M
-15.23M – -4.58M
-12.8% YoY
|
-17.25M
-30.76M – -9.25M
-102.0% YoY
|
| EBIT |
-72.76M
est: -1.29M (-5,545.0%)
|
-97.25M
est: -6.65M (-1,362.2%)
|
-119.35M
est: -14.67M (-713.3%)
|
-113.73M
est: -101.11M (-12.5%)
|
-140.92M
est: -292.05M (+51.7%)
|
-134.84M
est: -118.98M (-13.3%)
|
-193.15M
est: -203.95M (+5.3%)
|
-225.95M
est: -170.98M (-32.1%)
|
-169.18M
est: -67.03M (-152.4%)
|
-238.92M
est: -34.36M (-595.4%)
|
-153.89M
est: -24.14M (-537.6%)
|
-14.80M
-21.96M – -10.32M
+38.7% YoY
|
-13.48M
-17.38M – -11.40M
+8.9% YoY
|
-7.57M
-13.51M – -4.06M
+43.8% YoY
|
-8.54M
-15.23M – -4.58M
-12.8% YoY
|
-17.25M
-30.76M – -9.25M
-102.0% YoY
|
| Net Income |
-72.90M
est: -432.32M (+83.1%)
|
-97.18M
est: -206.05M (+52.8%)
|
-120.32M
est: -237.62M (+49.4%)
|
-109.95M
est: -97.77M (-12.5%)
|
-133.75M
est: -278.57M (+52.0%)
|
-115.98M
est: -98.81M (-17.4%)
|
-192.50M
est: -203.25M (+5.3%)
|
-220.43M
est: -226.29M (+2.6%)
|
-153.22M
est: -193.45M (+20.8%)
|
-237.09M
est: -236.86M (-0.1%)
|
-160.06M
est: -176.40M (+9.3%)
|
-79.93M
-107.43M – -52.43M
+54.7% YoY
|
-77.63M
-115.80M – -39.46M
+2.9% YoY
|
-94.12M
-104.38M – -83.86M
-21.2% YoY
|
-95.00M
-191.73M – -37.73M
-0.9% YoY
|
-95.03M
-191.79M – -37.75M
0.0% YoY
|
| SGA |
18.10M
est: 2.69M (+572.8%)
|
46.26M
est: 13.88M (+233.4%)
|
50.50M
est: 30.62M (+64.9%)
|
55.01M
est: 96.89M (-43.2%)
|
64.56M
est: 116.97M (-44.8%)
|
67.58M
est: 177.69M (-62.0%)
|
76.18M
est: 36.32M (+109.7%)
|
70.70M
est: 34.61M (+104.3%)
|
69.65M
est: 146.40M (-52.4%)
|
71.99M
est: 75.04M (-4.1%)
|
49.90M
est: 52.71M (-5.3%)
|
32.33M
22.54M – 47.97M
-38.7% YoY
|
29.45M
24.90M – 37.96M
-8.9% YoY
|
16.54M
8.87M – 29.50M
-43.8% YoY
|
18.65M
10.00M – 33.26M
+12.8% YoY
|
37.67M
20.21M – 67.18M
+102.0% YoY
|
| EPS |
-2.04
est: -5.25 (+61.1%)
|
-3.02
est: -2.50 (-20.7%)
|
-2.98
est: -2.89 (-3.3%)
|
-2.33
est: -2.06 (-13.0%)
|
-2.47
est: -1.83 (-35.1%)
|
-1.98
est: -1.70 (-16.3%)
|
-2.85
est: -3.01 (+5.4%)
|
-3.21
est: -3.05 (-5.3%)
|
-2.02
est: -2.36 (+14.4%)
|
-2.88
est: -2.70 (-6.6%)
|
-1.80
est: -1.98 (+9.0%)
|
-1.01
-1.21 – -0.59
+49.1% YoY
|
-0.97
-1.30 – -0.44
+4.0% YoY
|
-1.05
-1.18 – -0.94
-8.7% YoY
|
-1.07
-2.16 – -0.43
-1.9% YoY
|
-1.07
-2.16 – -0.43
0.0% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-05 | Chardan Capital | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-138.36M
OE per share TTM
-1.56
Owner's Yield
-40.85%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
95.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
212
Total invested
129.24M
Insider transactions (90d)
0
Beneficial owners (>5%)
34
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | STATE STREET CORPORATION | 7.88M | 11.00% | — | 7.73M | — | 7.88M | HC | BOSTON, MASSACHUSETTS | 2022-07-11 | ↗ |
| 2 | The Vanguard Group - 23-1945930 | 7.33M | 10.69% | — | 130.7K | 7.14M | 189.8K | IA | Pennsylvania | 2022-03-09 | ↗ |
| 3 | (1) BlackRock, Inc. | 6.98M | 10.20% | 6.71M | — | 6.98M | — | HC | Delaware | 2022-10-07 | ↗ |
| 4 | SSGA FUNDS MANAGEMENT, INC. | 6.58M | 9.59% | — | 6.56M | — | 6.58M | IA | BOSTON, MASSACHUSETTS | 2022-07-11 | ↗ |
| 5 | Abigail P. Johnson | 5.12M | 14.36% | — | — | 5.12M | — | IN | Delaware | 2016-03-10 | ↗ |
| 6 | FMR LLC | 5.12M | 14.36% | 482.9K | — | 5.12M | — | HC | Delaware | 2016-03-10 | ↗ |
| 7 | Sumitomo Mitsui Trust Holdings, Inc. (“SMTH”) | 4.96M | 10.01% | — | 4.96M | — | — | FI, HC | Japan | 2019-10-10 | ↗ |
| 8 | David Kroin | 4.49M | 5.51% | — | 4.49M | — | — | HC, IN | United States | 2023-08-04 | ↗ |
| 9 | Deep Track Biotechnology Master Fund, Ltd. | 4.49M | 5.51% | — | 4.49M | — | — | CO | Cayman Islands | 2023-08-04 | ↗ |
| 10 | Deep Track Capital, LP | 4.49M | 5.51% | — | 4.49M | — | — | IA, OO | Delaware | 2023-08-04 | ↗ |
| 11 | ARK Investment Management LLC | 4.45M | 8.67% | 3.40M | 322.6K | 4.45M | — | IA | OR PLACE OF ORGANIZATION | 2020-02-14 | ↗ |
| 12 | Nikko Asset Management Americas, Inc. | 4.39M | 7.04% | — | 3.70M | — | 4.39M | IA | USA | 2021-02-11 | ↗ |
| 13 | 10. | 3.91M | 10.70% | — | 3.91M | — | 3.91M | OO | of 12 Pages | 2017-02-13 | ↗ |
| 14 | Daniel S. Sundheim | 2.73M | 7.50% | — | 2.73M | — | 2.73M | IN | Delaware | 2016-02-09 | ↗ |
| 15 | David C. Ott | 2.73M | 7.50% | — | 2.73M | — | 2.73M | IN | Delaware | 2016-02-09 | ↗ |
| 16 | O. Andreas Halvorsen | 2.73M | 7.50% | — | 2.73M | — | 2.73M | IN | Delaware | 2016-02-09 | ↗ |
| 17 | Viking Global Investors LP | 2.73M | 7.50% | — | 2.73M | — | 2.73M | PN | Delaware | 2016-02-09 | ↗ |
| 18 | (“SMTH”) | 2.68M | 3.91% | — | 2.68M | — | 2.68M | FI, HC | Japan | 2022-02-04 | ↗ |
| 19 | Nikko Asset Management Co., Ltd. (“NAM”) | 2.68M | 3.91% | — | 2.68M | — | 2.68M | FI, IA, HC | Japan | 2022-02-04 | ↗ |
| 20 | Viking Global Opportunities GP LLC | 1.71M | 4.70% | — | 1.71M | — | 1.71M | OO | Delaware | 2016-02-09 | ↗ |
| 21 | Viking Global Opportunities Illiquid Investments Sub-Master LP | 1.71M | 4.70% | — | 1.71M | — | 1.71M | PN | Delaware | 2016-02-09 | ↗ |
| 22 | Viking Global Opportunities Portfolio GP LLC | 1.71M | 4.70% | — | 1.71M | — | 1.71M | OO | Delaware | 2016-02-09 | ↗ |
| 23 | Deerfield Management Company, L.P. | 1.71M | 4.66% | — | 1.71M | — | — | PN | Delaware | 2017-02-14 | ↗ |
| 24 | James E. Flynn | 1.71M | 4.66% | — | 1.71M | — | — | IN | Delaware | 2017-02-14 | ↗ |
| 25 | Deerfield Healthcare Innovations Fund, L.P. | 854.7K | 2.33% | — | 854.7K | — | — | PN | Delaware | 2017-02-14 | ↗ |
| 26 | Deerfield Mgmt HIF, L.P. | 854.7K | 2.33% | — | 854.7K | — | — | PN | Delaware | 2017-02-14 | ↗ |
| 27 | Deerfield Mgmt III, L.P. | 854.7K | 2.33% | — | 854.7K | — | — | PN | Delaware | 2017-02-14 | ↗ |
| 28 | Deerfield Private Design Fund III, L.P. | 854.7K | 2.33% | — | 854.7K | — | — | PN | Delaware | 2017-02-14 | ↗ |
| 29 | Viking Global Performance LLC | 753.6K | 2.10% | — | 753.6K | — | 753.6K | OO | Delaware | 2016-02-09 | ↗ |
| 30 | VGE III Portfolio Ltd. | 481.6K | 1.30% | — | 481.6K | — | 481.6K | CO | Delaware | 2016-02-09 | ↗ |
| 31 | Viking Long Fund GP LLC | 266.8K | 0.70% | — | 266.8K | — | 266.8K | OO | Delaware | 2016-02-09 | ↗ |
| 32 | Viking Long Fund Master Ltd. | 266.8K | 0.70% | — | 266.8K | — | 266.8K | CO | Delaware | 2016-02-09 | ↗ |
| 33 | Viking Global Equities LP | 257.0K | 0.70% | — | 257.0K | — | 257.0K | PN | Delaware | 2016-02-09 | ↗ |
| 34 | Viking Global Equities II LP | 15.1K | 0.00% | — | 15.1K | — | 15.1K | PN | Delaware | 2016-02-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
212
+6 vs prev Q
New positions
39
Closed positions
31
Increased
100
Reduced
47
Put/Call ratio
0.69
Calls held
375.2K
Puts held
258.2K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 9.35M +1.3M (+16.5%) | 19.16M -8.7M (-31.1%) | 10.38% +0.874 pp | 0.00% 0.000 pp | USD3.21 -36.1% | 6 qtrs — |
| 2 | VANGUARD GROUP INC | 8.21M +1.2M (+17.8%) | 16.83M -7.3M (-30.4%) | 9.11% +0.859 pp | 0.00% 0.000 pp | USD18.66 -89.0% | 40 qtrs — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 3.04M +1.8M (+138.0%) | 6.23M +1.8M (+40.6%) | 3.37% +1.861 pp | 0.01% +0.004 pp | USD2.00 +2.5% | 11 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 2.28M +244.6K (+12.0%) | 4.68M -2.4M (-33.8%) | 2.54% +0.119 pp | 0.00% 0.000 pp | USD17.48 -88.3% | 40 qtrs — |
| 5 | NUVEEN, LLC | 1.98M -114.7K (-5.5%) | 4.05M -3.2M (-44.2%) | 2.19% -0.284 pp | 0.00% -0.001 pp | USD2.74 -25.2% | 4 qtrs — |
| 6 | STATE STREET CORP | 1.97M +49.9K (+2.6%) | 4.05M -2.6M (-39.4%) | 2.19% -0.088 pp | 0.00% 0.000 pp | USD12.31 -83.3% | 40 qtrs — |
| 7 | TWO SIGMA INVESTMENTS, LP | 1.63M +48.4K (+3.1%) | 3.35M -2.2M (-39.1%) | 1.81% -0.065 pp | 0.00% -0.004 pp | USD5.82 -64.8% | 31 qtrs — |
| 8 | TWO SIGMA ADVISERS, LP | 1.22M +19.1K (+1.6%) | 2.51M -1.7M (-40.0%) | 1.36% -0.069 pp | 0.00% -0.004 pp | USD9.11 -77.5% | 33 qtrs — |
| 9 | RAYMOND JAMES FINANCIAL INC | 1.18M +1.0M (+622.9%) | 2.43M +1.9M (+327.0%) | 1.32% +1.121 pp | 0.00% +0.001 pp | USD1.94 +5.7% | 5 qtrs — |
| 10 | JANE STREET GROUP, LLC | 1.18M +660.0K (+127.8%) | 2.41M +619.4K (+34.6%) | 1.31% +0.694 pp | 0.00% +0.000 pp | USD2.88 -28.8% | 25 qtrs — |
| 11 | D. E. SHAW & CO., INC. | 1.11M +993.4K (+855.1%) | 2.27M +1.9M (+464.2%) | 1.23% +1.094 pp | 0.00% +0.001 pp | USD2.36 -13.1% | 37 qtrs — |
| 12 | GOLDMAN SACHS GROUP INC | 882.0K +423.7K (+92.5%) | 1.81M +217.8K (+13.7%) | 0.98% +0.436 pp | 0.00% +0.000 pp | USD5.09 -59.7% | 40 qtrs — |
| 13 | JACOBS LEVY EQUITY MANAGEMENT, INC | 827.1K +27.1K (+3.4%) | 1.70M -1.1M (-38.9%) | 0.92% -0.030 pp | 0.01% -0.005 pp | USD3.28 -37.5% | 16 qtrs — |
| 14 | CITADEL ADVISORS LLC | 821.0K +458.8K (+126.7%) | 1.68M +426.2K (+33.9%) | 0.91% +0.482 pp | 0.00% +0.000 pp | USD2.28 -10.1% | 31 qtrs — |
| 15 | UBS GROUP AG | 809.3K +386.9K (+91.6%) | 1.66M +193.4K (+13.2%) | 0.90% +0.398 pp | 0.00% +0.000 pp | USD2.74 -25.2% | 40 qtrs — |
| 16 | ACADIAN ASSET MANAGEMENT LLC | 799.8K +443.2K (+124.3%) | 1.64M +399.0K (+32.3%) | 0.89% +0.465 pp | 0.00% +0.001 pp | USD1.67 +22.8% | 5 qtrs — |
| 17 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 794.7K +14.7K (+1.9%) | 1.63M -1.1M (-39.8%) | 0.88% -0.042 pp | 0.00% 0.000 pp | USD15.80 -87.0% | 40 qtrs — |
| 18 | JPMORGAN CHASE & CO | 783.1K -37.6K (-4.6%) | 1.61M -1.2M (-43.6%) | 0.87% -0.103 pp | 0.00% 0.000 pp | USD27.03 -92.4% | 40 qtrs — |
| 19 | POINT72 ASSET MANAGEMENT, L.P. | 733.5K +733.5K (+100.0%) | 1.50M +1.5M (+100.0%) | 0.81% +0.814 pp | 0.00% +0.002 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 20 | MORGAN STANLEY | 678.9K -409.0K (-37.6%) | 1.39M -2.4M (-63.1%) | 0.75% -0.535 pp | 0.00% 0.000 pp | USD6.56 -68.8% | 40 qtrs — |
| 21 | NORTHERN TRUST CORP | 662.5K -7.2K (-1.1%) | 1.36M -965.8K (-41.6%) | 0.74% -0.058 pp | 0.00% 0.000 pp | USD18.83 -89.1% | 40 qtrs — |
| 22 | AQR CAPITAL MANAGEMENT LLC | 644.2K -43.6K (-6.3%) | 1.32M -1.1M (-44.7%) | 0.72% -0.100 pp | 0.00% -0.001 pp | USD2.13 -3.8% | 13 qtrs — |
| 23 | GSA CAPITAL PARTNERS LLP | 568.8K +568.8K (+100.0%) | 1.17M +1.2M (+100.0%) | 0.63% +0.631 pp | 0.10% +0.100 pp | USD2.05 +0.0% | 3 qtrs — |
| 24 | KENNEDY CAPITAL MANAGEMENT LLC | 562.1K -3.5K (-0.6%) | 1.15M -810.4K (-41.3%) | 0.62% -0.046 pp | 0.02% -0.019 pp | USD4.20 -51.2% | 8 qtrs — |
| 25 | DIMENSIONAL FUND ADVISORS LP | 335.5K -596.4K (-64.0%) | 687.7K -2.5M (-78.7%) | 0.37% -0.732 pp | 0.00% -0.001 pp | USD18.15 -88.7% | 22 qtrs — |
| 26 | DIADEMA PARTNERS LP | 318.7K +18.7K (+6.2%) | 653.3K -387.7K (-37.2%) | 0.35% -0.002 pp | 0.11% -0.154 pp | USD3.39 -39.5% | 2 qtrs — |
| 27 | EVERSEPT PARTNERS, LP | 290.9K +290.9K (+100.0%) | 596.4K +596.4K (+100.0%) | 0.32% +0.323 pp | 0.03% +0.030 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 28 | HENNION & WALSH ASSET MANAGEMENT, INC. | 279.5K +37.8K (+15.7%) | 573.0K -265.6K (-31.7%) | 0.31% +0.024 pp | 0.02% -0.011 pp | USD3.59 -42.9% | 7 qtrs — |
| 29 | BARCLAYS PLC | 276.3K +97.8K (+54.8%) | 566.3K -42.4K (-7.0%) | 0.31% +0.095 pp | 0.00% +0.000 pp | USD5.35 -61.7% | 40 qtrs — |
| 30 | XTX TOPCO LTD | 246.6K -13.5K (-5.2%) | 505.5K -397.1K (-44.0%) | 0.27% -0.034 pp | 0.01% -0.034 pp | USD2.42 -15.3% | 14 qtrs — |
| 31 | BANK OF NEW YORK MELLON CORP | 245.3K -19.3K (-7.3%) | 503.0K -415.5K (-45.2%) | 0.27% -0.041 pp | 0.00% 0.000 pp | USD22.92 -91.1% | 40 qtrs — |
| 32 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 244.4K -64.0K (-20.7%) | 500.9K -569.0K (-53.2%) | 0.27% -0.094 pp | 0.01% -0.009 pp | USD3.47 -40.9% | 2 qtrs — |
| 33 | BANK OF AMERICA CORP /DE/ | 193.7K -830.6K (-81.1%) | 397.0K -3.2M (-88.8%) | 0.22% -0.998 pp | 0.00% 0.000 pp | USD3.41 -39.9% | 40 qtrs — |
| 34 | AMERIPRISE FINANCIAL INC | 187.9K -250.0 (-0.1%) | 385.2K -267.7K (-41.0%) | 0.21% -0.014 pp | 0.00% 0.000 pp | USD3.47 -40.9% | 2 qtrs — |
| 35 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 181.6K +3.2K (+1.8%) | 372.0K -247.0K (-39.9%) | 0.20% -0.010 pp | 0.00% -0.001 pp | USD19.24 -89.3% | 25 qtrs — |
| 36 | ALLIANCEBERNSTEIN L.P. | 167.5K +— (+0.0%) | 343.4K -237.9K (-40.9%) | 0.19% -0.013 pp | 0.00% 0.000 pp | USD12.92 -84.1% | 39 qtrs — |
| 37 | WELLS FARGO & COMPANY/MN | 162.7K +34.4K (+26.8%) | 333.6K -111.6K (-25.1%) | 0.18% +0.029 pp | 0.00% +0.000 pp | USD8.43 -75.7% | 40 qtrs — |
| 38 | MILLENNIUM MANAGEMENT LLC | 162.3K -173.5K (-51.7%) | 332.8K -832.4K (-71.4%) | 0.18% -0.218 pp | 0.00% 0.000 pp | USD3.12 -34.3% | 29 qtrs — |
| 39 | GREEN ALPHA ADVISORS, LLC | 161.1K +14.7K (+10.0%) | 330.3K -177.8K (-35.0%) | 0.18% +0.005 pp | 0.30% -0.188 pp | USD3.36 -39.0% | 21 qtrs — |
| 40 | LOS ANGELES CAPITAL MANAGEMENT LLC | 97.8K -19.9K (-16.9%) | 294.4K -113.9K (-27.9%) | 0.11% -0.031 pp | 0.00% 0.000 pp | USD4.89 -58.1% | 8 qtrs — |
| 41 | FMR LLC | 141.7K +42.0K (+42.1%) | 290.4K -55.4K (-16.0%) | 0.16% +0.039 pp | 0.00% +0.000 pp | USD4.06 -49.5% | 40 qtrs — |
| 42 | GRAHAM CAPITAL MANAGEMENT, L.P. | 139.9K +72.8K (+108.6%) | 286.8K +54.0K (+23.2%) | 0.16% +0.076 pp | 0.01% +0.003 pp | USD2.36 -13.1% | 3 qtrs — |
| 43 | SIMPLEX TRADING, LLC | 139.8K -92.1K (-39.7%) | 286.5K -517.5K (-64.4%) | 0.16% -0.120 pp | 0.00% 0.000 pp | USD2.87 -28.6% | 14 qtrs — |
| 44 | WALLEYE CAPITAL LLC | 119.4K -274.4K (-69.7%) | 244.8K -1.1M (-82.1%) | 0.13% -0.334 pp | 0.00% -0.004 pp | USD3.47 -40.9% | 2 qtrs — |
| 45 | WALLEYE TRADING LLC | 117.1K +111.1K (+1,851.7%) | 240.1K +219.2K (+1,053.0%) | 0.13% +0.123 pp | 0.00% +0.000 pp | USD2.12 -3.3% | 2 qtrs — |
| 46 | HSBC HOLDINGS PLC | 112.2K +16.3K (+17.0%) | 230.5K -95.0K (-29.2%) | 0.12% +0.011 pp | 0.00% 0.000 pp | USD4.29 -52.2% | 12 qtrs — |
| 47 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 109.7K +46.2K (+72.8%) | 224.9K +4.5K (+2.1%) | 0.12% +0.047 pp | 0.00% +0.000 pp | USD7.79 -73.7% | 36 qtrs — |
| 48 | RHUMBLINE ADVISERS | 109.3K -13.2K (-10.8%) | 224.1K -201.1K (-47.3%) | 0.12% -0.024 pp | 0.00% 0.000 pp | USD18.07 -88.7% | 35 qtrs — |
| 49 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 108.5K +68.2K (+169.2%) | 222.5K +82.6K (+59.0%) | 0.12% +0.073 pp | 0.00% +0.000 pp | USD2.97 -31.0% | 7 qtrs — |
| 50 | QUADRATURE CAPITAL LTD | 107.4K +107.4K (+100.0%) | 220.1K +220.1K (+100.0%) | 0.12% +0.119 pp | 0.00% +0.002 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 51 | RUSSELL INVESTMENTS GROUP, LTD. | 95.5K +16.9K (+21.6%) | 195.8K -76.8K (-28.2%) | 0.11% +0.013 pp | 0.00% 0.000 pp | USD3.31 -38.1% | 24 qtrs — |
| 52 | PRICE T ROWE ASSOCIATES INC /MD/ | 92.4K +6.2K (+7.2%) | 190.0K -110.0K (-36.7%) | 0.10% +0.000 pp | 0.00% +0.000 pp | USD10.92 -81.2% | 22 qtrs — |
| 53 | SQUAREPOINT OPS LLC | 91.8K +29.8K (+48.0%) | 188.3K -27.1K (-12.6%) | 0.10% +0.028 pp | 0.00% +0.000 pp | USD3.01 -31.9% | 2 qtrs — |
| 54 | IEQ CAPITAL, LLC | 89.2K -61.5K (-40.8%) | 182.8K -340.0K (-65.0%) | 0.10% -0.080 pp | 0.00% -0.001 pp | USD1.18 +73.7% | 5 qtrs — |
| 55 | ENTRYPOINT CAPITAL, LLC | 84.6K +84.6K (+100.0%) | 173.3K +173.3K (+100.0%) | 0.09% +0.094 pp | 0.07% +0.068 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 56 | MAN GROUP PLC | 79.2K +29.3K (+58.8%) | 162.3K -10.7K (-6.2%) | 0.09% +0.029 pp | 0.00% +0.000 pp | USD2.94 -30.3% | 2 qtrs — |
| 57 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 76.0K +— (+0.0%) | 155.8K -107.9K (-40.9%) | 0.08% -0.006 pp | 0.00% -0.002 pp | USD2.04 +0.5% | 5 qtrs — |
| 58 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 75.5K +— (+0.0%) | 154.8K -107.2K (-40.9%) | 0.08% -0.006 pp | 0.00% 0.000 pp | USD3.47 -40.9% | 2 qtrs — |
| 59 | SEI INVESTMENTS CO | 74.2K +60.9K (+457.3%) | 152.1K +105.9K (+229.3%) | 0.08% +0.067 pp | 0.00% +0.000 pp | USD2.30 -10.9% | 5 qtrs — |
| 60 | TEXAS YALE CAPITAL CORP. | 70.0K +— (+0.0%) | 143.5K -99.4K (-40.9%) | 0.08% -0.005 pp | 0.00% -0.003 pp | USD30.74 -93.3% | 21 qtrs — |
| 61 | JOEL ISAACSON & CO., LLC | 68.1K +68.1K (+100.0%) | 139.7K +139.7K (+100.0%) | 0.08% +0.076 pp | 0.00% +0.005 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 62 | LPL FINANCIAL LLC | 64.9K +23.4K (+56.6%) | 133.0K -10.7K (-7.5%) | 0.07% +0.023 pp | 0.00% +0.000 pp | USD12.32 -83.4% | 32 qtrs — |
| 63 | PEAK6 LLC | 59.8K +59.8K (+100.0%) | 122.6K +122.6K (+100.0%) | 0.07% +0.066 pp | 0.00% +0.000 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 64 | ADVISOR GROUP HOLDINGS, INC. | 57.8K +41.8K (+261.7%) | 118.4K +64.9K (+121.2%) | 0.06% +0.045 pp | 0.00% +0.000 pp | USD4.55 -54.9% | 24 qtrs — |
| 65 | INVESCO LTD. | 54.9K -4.8K (-8.1%) | 112.5K -94.7K (-45.7%) | 0.06% -0.010 pp | 0.00% +0.000 pp | USD24.39 -91.6% | 29 qtrs — |
| 66 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 48.9K -2.1K (-4.1%) | 104.5K -95.5K (-47.8%) | 0.05% -0.006 pp | 0.00% 0.000 pp | USD1.32 +55.3% | 5 qtrs — |
| 67 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 45.1K -665.0 (-1.5%) | 92.0K -69.0K (-42.9%) | 0.05% -0.004 pp | 0.00% 0.000 pp | USD3.90 -47.4% | 39 qtrs — |
| 68 | STIFEL FINANCIAL CORP | 44.8K -535.4K (-92.3%) | 91.9K -1.9M (-95.4%) | 0.05% -0.638 pp | 0.00% -0.002 pp | USD4.78 -57.1% | 21 qtrs — |
| 69 | CWM, LLC | 44.2K -462.0 (-1.0%) | 91.0K -64.0K (-41.3%) | 0.05% -0.004 pp | 0.00% 0.000 pp | USD1.70 +20.6% | 17 qtrs — |
| 70 | TWO SIGMA SECURITIES, LLC | 43.9K +43.9K (+100.0%) | 89.9K +89.9K (+100.0%) | 0.05% +0.049 pp | 0.01% +0.012 pp | USD2.05 +0.0% | 3 qtrs — |
| 71 | VIRTU FINANCIAL LLC | 43.2K +43.2K (+100.0%) | 89.0K +89.0K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.003 pp | USD2.05 +0.0% | 5 qtrs — |
| 72 | MARINER, LLC | 41.3K -36.1K (-46.6%) | 84.7K -183.9K (-68.5%) | 0.05% -0.046 pp | 0.00% 0.000 pp | USD2.30 -10.9% | 8 qtrs — |
| 73 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 41.0K +— (+0.0%) | 84.1K -58.3K (-40.9%) | 0.05% -0.003 pp | 0.00% -0.001 pp | USD2.11 -2.8% | 6 qtrs — |
| 74 | INTECH INVESTMENT MANAGEMENT LLC | 39.7K -2.5K (-5.9%) | 81.5K -65.1K (-44.4%) | 0.04% -0.006 pp | 0.00% -0.001 pp | USD2.04 +0.5% | 6 qtrs — |
| 75 | MML INVESTORS SERVICES, LLC | 37.9K -11.2K (-22.9%) | 77.6K -92.7K (-54.4%) | 0.04% -0.016 pp | 0.00% 0.000 pp | USD3.86 -46.9% | 14 qtrs — |
| 76 | SCS CAPITAL MANAGEMENT LLC | 35.0K +— (+0.0%) | 71.8K -49.7K (-40.9%) | 0.04% -0.003 pp | 0.00% -0.001 pp | USD1.16 +76.7% | 4 qtrs — |
| 77 | THRIVE WEALTH MANAGEMENT, LLC | 33.5K +— (+0.0%) | 68.7K -47.6K (-40.9%) | 0.04% -0.003 pp | 0.01% -0.007 pp | USD1.25 +64.0% | 9 qtrs — |
| 78 | BNP PARIBAS ARBITRAGE, SNC | 33.0K +5.8K (+21.4%) | 67.6K -26.6K (-28.3%) | 0.04% +0.004 pp | 0.00% +0.000 pp | USD3.82 -46.3% | 39 qtrs — |
| 79 | INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 31.0K -1.0K (-3.1%) | 63.6K -8.5K (-11.7%) | 0.03% -0.004 pp | 0.00% -0.001 pp | USD2.20 -6.8% | 11 qtrs — |
| 80 | HORIZON KINETICS ASSET MANAGEMENT LLC | 30.3K -1.3K (-4.2%) | 62.2K -47.7K (-43.4%) | 0.03% -0.004 pp | 0.00% -0.001 pp | USD6.86 -70.1% | 12 qtrs — |
| 81 | PRIME CAPITAL INVESTMENT ADVISORS, LLC | 28.5K -678.0 (-2.3%) | 58.5K -42.9K (-42.3%) | 0.03% -0.003 pp | 0.00% -0.001 pp | USD1.27 +61.4% | 5 qtrs — |
| 82 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 28.4K -287.0 (-1.0%) | 58.1K -41.3K (-41.5%) | 0.03% -0.003 pp | 0.00% +0.000 pp | USD21.03 -90.3% | 39 qtrs — |
| 83 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 23.0K +425.0 (+1.9%) | 47.1K -31.1K (-39.8%) | 0.03% -0.001 pp | 0.00% 0.000 pp | USD3.44 -40.4% | 2 qtrs — |
| 84 | BAIRD FINANCIAL GROUP, INC. | 20.9K -7.7K (-26.9%) | 42.8K -56.3K (-56.8%) | 0.02% -0.011 pp | 0.00% 0.000 pp | USD13.16 -84.4% | 17 qtrs — |
| 85 | PROSHARE ADVISORS LLC | 20.8K +3.2K (+17.9%) | 42.6K -18.6K (-30.3%) | 0.02% +0.002 pp | 0.00% 0.000 pp | USD13.40 -84.7% | 37 qtrs — |
| 86 | COMMONWEALTH EQUITY SERVICES, LLC | 20.2K -1.9K (-8.7%) | 41.3K -35.7K (-46.4%) | 0.02% -0.004 pp | 0.00% +0.000 pp | USD6.19 -66.9% | 8 qtrs — |
| 87 | METLIFE INVESTMENT MANAGEMENT, LLC | 17.0K -21.5K (-55.8%) | 34.9K -98.8K (-73.9%) | 0.02% -0.027 pp | 0.00% -0.001 pp | USD2.20 -6.8% | 3 qtrs — |
| 88 | HCR WEALTH ADVISORS | 17.0K +— (+0.0%) | 34.9K -31.3K (-47.3%) | 0.02% -0.001 pp | 0.00% -0.003 pp | USD21.46 -90.4% | 24 qtrs — |
| 89 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 16.8K -11.1K (-39.8%) | 34.5K -62.5K (-64.4%) | 0.02% -0.014 pp | 0.00% -0.001 pp | USD2.15 -4.7% | 5 qtrs — |
| 90 | DLK INVESTMENT MANAGEMENT, LLC | 16.6K -12.7K (-43.3%) | 34.1K -67.7K (-66.5%) | 0.02% -0.016 pp | 0.01% -0.026 pp | USD6.28 -67.4% | 9 qtrs — |
| 91 | SG AMERICAS SECURITIES, LLC | 16.8K +2.0K (+13.9%) | 34.0K -17.0K (-33.3%) | 0.02% +0.001 pp | 0.00% 0.000 pp | USD3.30 -37.9% | 6 qtrs — |
| 92 | VOYA INVESTMENT MANAGEMENT LLC | 16.1K +— (+0.0%) | 33.0K -22.8K (-40.9%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD27.44 -92.5% | 35 qtrs — |
| 93 | CETERA INVESTMENT ADVISERS | 16.1K +— (+0.0%) | 33.0K -22.8K (-40.9%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD3.47 -40.9% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 62 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree BioRevolution UCITS ETF - USD Acc WDNA.L | 1.05% | 234.6K | 0.45% |
| 2 | ROBO Global Healthcare Technology and Innovation ETF HTEC | 0.59% | 292.8K | 0.68% |
| 3 | Horizon Kinetics Medical ETF MEDX | 0.49% | 90.2K | 0.85% |
| 4 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.47% | 103.3K | 0.20% |
| 5 | AXS Green Alpha ETF NXTE | 0.39% | 226.6K | 1.00% |
| 6 | Global X - Genomics & Biotechnology ETF GNOM | 0.28% | 244.9K | 0.50% |
| 7 | Global X - Genomics & Biotechnology UCITS ETF GNOM.L | 0.28% | 146.7K | 0.50% |
| 8 | iShares Micro-Cap ETF IWC | 0.07% | 1.10M | 0.60% |
| 9 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.04% | 408.0K | 0.40% |
| 10 | iShares Biotechnology ETF IBB | 0.04% | 3.33M | 0.44% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
3
Shares acquired
—
Shares disposed
6.6K
Cash buys
—
Cash sales
3.00
Net activity
-6,617
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-12 | Parison Amy | Officer | A-Award | A | Stock Option (right to buy) | 292,856 | 2.54 | 743.9K | 292,856 | D | ↗ |
| 2026-03-12 | O'Neill Gilmore Neil | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,015,200 | 2.54 | 2.58M | 1,015,200 | D | ↗ |
| 2026-03-12 | Burkly Linda | Officer | A-Award | A | Stock Option (right to buy) | 292,856 | 2.54 | 743.9K | 292,856 | D | ↗ |
| 2026-03-03 | Parison Amy | Officer | S-Sale | D | Common Stock | 474 | 2.02 | 957.48 | 15,434 | D | ↗ |
| 2026-03-03 | O'Neill Gilmore Neil | Director / Officer | S-Sale | D | Common Stock | 5,394 | 2.02 | 10.9K | 263,693 | D | ↗ |
| 2026-03-03 | Burkly Linda | Officer | S-Sale | D | Common Stock | 749 | 2.02 | 1.5K | 68,028 | D | ↗ |
| 2025-12-03 | Parison Amy | Officer | S-Sale | D | Common Stock | 461 | 2.15 | 992.58 | 15,908 | D | ↗ |
| 2025-12-03 | O'Neill Gilmore Neil | Director / Officer | S-Sale | D | Common Stock | 5,603 | 2.15 | 12.1K | 269,087 | D | ↗ |
| 2025-12-03 | Burkly Linda | Officer | S-Sale | D | Common Stock | 713 | 2.15 | 1.5K | 68,777 | D | ↗ |
| 2025-09-03 | Parison Amy | Officer | S-Sale | D | Common Stock | 458 | 2.60 | 1.2K | 16,369 | D | ↗ |
| 2025-09-03 | O'Neill Gilmore Neil | Director / Officer | S-Sale | D | Common Stock | 5,592 | 2.60 | 14.5K | 274,690 | D | ↗ |
| 2025-09-03 | Burkly Linda | Officer | S-Sale | D | Common Stock | 710 | 2.60 | 1.8K | 69,490 | D | ↗ |
| 2025-08-07 | Parison Amy | Officer | S-Sale | D | Common Stock | 679 | 2.58 | 1.8K | 16,827 | D | ↗ |
| 2025-07-31 | Burkly Linda | Officer | S-Sale | D | Common Stock | 5,121 | 2.49 | 12.8K | 64,398 | D | ↗ |
| 2025-06-06 | Scadden David | Director | A-Award | A | Stock Option (right to buy) | 37,500 | 1.91 | 71.6K | 37,500 | D | ↗ |
| 2025-06-06 | Levy Elliott M. | Director | A-Award | A | Stock Option (right to buy) | 37,500 | 1.91 | 71.6K | 37,500 | D | ↗ |
| 2025-06-06 | Hopfield Jessica | Director | A-Award | A | Stock Option (right to buy) | 37,500 | 1.91 | 71.6K | 37,500 | D | ↗ |
| 2025-06-06 | Hirsch Andrew | Director | A-Award | A | Stock Option (right to buy) | 37,500 | 1.91 | 71.6K | 37,500 | D | ↗ |
| 2025-06-06 | Connaughton Bernadette | Director | A-Award | A | Stock Option (right to buy) | 37,500 | 1.91 | 71.6K | 37,500 | D | ↗ |
| 2025-06-03 | Parison Amy | Officer | S-Sale | D | Common Stock | 446 | 1.72 | 768.90 | 17,506 | D | ↗ |
| 2025-06-03 | O'Neill Gilmore Neil | Director / Officer | S-Sale | D | Common Stock | 15,192 | 1.72 | 26.2K | 280,282 | D | ↗ |
| 2025-06-03 | Burkly Linda | Officer | S-Sale | D | Common Stock | 726 | 1.72 | 1.3K | 69,519 | D | ↗ |
| 2025-04-08 | Parison Amy | Officer | A-Award | A | Stock Option (right to buy) | 34,672 | 0.98 | 34.0K | 34,672 | D | ↗ |
| 2025-03-28 | Parison Amy | Officer | — | — | Common Stock | 0 | 0.00 | — | 17,952 | D | ↗ |
| 2025-03-08 | O'Neill Gilmore Neil | Director / Officer | A-Award | A | Stock Option (right to buy) | 828,000 | 1.72 | 1.42M | 828,000 | D | ↗ |
| 2025-03-08 | Lucera Erick | Officer | A-Award | A | Stock Option (right to buy) | 275,100 | 1.72 | 473.2K | 275,100 | D | ↗ |
| 2025-03-08 | Burkly Linda | Officer | A-Award | A | Stock Option (right to buy) | 275,100 | 1.72 | 473.2K | 275,100 | D | ↗ |
| 2025-03-04 | O'Neill Gilmore Neil | Director / Officer | S-Sale | D | Common Stock | 16,632 | 1.71 | 28.5K | 295,474 | D | ↗ |
| 2025-03-04 | Lucera Erick | Officer | S-Sale | D | Common Stock | 4,109 | 1.71 | 7.0K | 112,720 | D | ↗ |
| 2025-03-04 | Burkly Linda | Officer | S-Sale | D | Common Stock | 2,891 | 1.71 | 4.9K | 70,245 | D | ↗ |
| 2024-12-03 | O'Neill Gilmore Neil | Director / Officer | S-Sale | D | Common Stock | 1,618 | 2.08 | 3.4K | 312,106 | D | ↗ |
| 2024-12-03 | Mei Baisong | Officer | S-Sale | D | Common Stock | 541 | 2.08 | 1.1K | 133,354 | D | ↗ |
| 2024-09-04 | O'Neill Gilmore Neil | Director / Officer | S-Sale | D | Common Stock | 1,555 | 3.42 | 5.3K | 313,724 | — | ↗ |
| 2024-09-04 | Mei Baisong | Officer | S-Sale | D | Common Stock | 518 | 3.42 | 1.8K | 133,895 | — | ↗ |
| 2024-07-25 | Burkly Linda | Officer | S-Sale | D | Common Stock | 11,886 | 5.42 | 64.4K | 73,136 | — | ↗ |
| 2024-07-19 | Mei Baisong | Officer | S-Sale | D | Common Stock | 6,619 | 5.21 | 34.5K | 134,413 | — | ↗ |
| 2024-06-04 | O'Neill Gilmore Neil | Director / Officer | S-Sale | D | Common Stock | 12,191 | 5.50 | 67.0K | 315,279 | — | ↗ |
| 2024-06-04 | Mei Baisong | Officer | S-Sale | D | Common Stock | 511 | 5.50 | 2.8K | 141,032 | — | ↗ |
| 2024-05-30 | Vaishnaw Akshay | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.17 | 129.3K | 25,000 | — | ↗ |
| 2024-05-30 | Scadden David | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.17 | 129.3K | 25,000 | — | ↗ |
| 2024-05-30 | Reeve Emma | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.17 | 129.3K | 25,000 | — | ↗ |
| 2024-05-30 | Levy Elliott M. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.17 | 129.3K | 25,000 | — | ↗ |
| 2024-05-30 | Hopfield Jessica | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.17 | 129.3K | 25,000 | — | ↗ |
| 2024-05-30 | Hirsch Andrew | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.17 | 129.3K | 25,000 | — | ↗ |
| 2024-05-30 | Connaughton Bernadette | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.17 | 129.3K | 25,000 | — | ↗ |
| 2024-05-30 | Chatterjee Meeta | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.17 | 129.3K | 25,000 | — | ↗ |
| 2024-05-20 | Lucera Erick | Officer | S-Sale | D | Common Stock | 22,337 | 5.61 | 125.4K | 116,829 | — | ↗ |
| 2024-05-13 | Hopfield Jessica | Director | P-Purchase | A | Common Stock | 45,000 | 5.64 | 253.9K | 67,700 | — | ↗ |
| 2024-03-05 | O'Neill Gilmore Neil | Director / Officer | S-Sale | D | Common Stock | 77,824 | 9.42 | 732.9K | 327,470 | — | ↗ |
| 2024-03-04 | Mei Baisong | Officer | S-Sale | D | Common Stock | 20,327 | 9.42 | 191.4K | 141,543 | — | ↗ |
| 2024-03-02 | O'Neill Gilmore Neil | Director / Officer | A-Award | A | Common Stock | 72,213 | 0.00 | — | 333,082 | — | ↗ |
| 2024-03-02 | Mei Baisong | Officer | A-Award | A | Common Stock | 50,900 | 0.00 | — | 122,955 | — | ↗ |
| 2024-03-02 | Lucera Erick | Officer | A-Award | A | Stock Option (right to buy) | 106,000 | 10.53 | 1.12M | 106,000 | — | ↗ |
| 2024-03-02 | Burkly Linda | Officer | A-Award | A | Stock Option (right to buy) | 74,400 | 10.53 | 783.4K | 74,400 | — | ↗ |
| 2023-12-05 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 103 | 10.90 | 1.1K | 74,791 | — | ↗ |
| 2023-11-14 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 695 | 8.21 | 5.7K | 74,894 | — | ↗ |
| 2023-11-07 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 139 | 8.40 | 1.2K | 75,589 | — | ↗ |
| 2023-09-06 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 103 | 8.82 | 908.46 | 75,728 | — | ↗ |
| 2023-08-11 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 702 | 8.59 | 6.0K | 75,831 | — | ↗ |
| 2023-08-08 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 141 | 8.39 | 1.2K | 76,533 | — | ↗ |
| 2023-07-24 | Burkly Linda | Officer | A-Award | A | Stock Option (right to buy) | 135,500 | 8.66 | 1.17M | 135,500 | — | ↗ |
| 2023-07-19 | Mei Baisong | Officer | S-Sale | D | Common Stock | 4,317 | 8.80 | 38.0K | 72,055 | — | ↗ |
| 2023-06-05 | O'Neill Gilmore Neil | Director / Officer | S-Sale | D | Common Stock | 6,486 | 9.50 | 61.6K | 130,169 | — | ↗ |
| 2023-06-05 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 105 | 9.50 | 997.82 | 76,674 | — | ↗ |
| 2023-06-01 | Vaishnaw Akshay | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 9.55 | 238.8K | 25,000 | — | ↗ |
| 2023-06-01 | Scadden David | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 9.55 | 238.8K | 25,000 | — | ↗ |
| 2023-06-01 | Reeve Emma | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 9.55 | 238.8K | 25,000 | — | ↗ |
| 2023-06-01 | Hopfield Jessica | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 9.55 | 238.8K | 25,000 | — | ↗ |
| 2023-06-01 | Hirsch Andrew | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 9.55 | 238.8K | 25,000 | — | ↗ |
| 2023-06-01 | Connaughton Bernadette | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 9.55 | 238.8K | 25,000 | — | ↗ |
| 2023-06-01 | Chatterjee Meeta | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 9.55 | 238.8K | 25,000 | — | ↗ |
| 2023-05-17 | Lucera Erick | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-11 | ROBERTSON MICHELLE | Officer | S-Sale | D | Common Stock | 949 | 9.87 | 9.4K | 106,610 | — | ↗ |
| 2023-05-11 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 668 | 9.87 | 6.6K | 76,779 | — | ↗ |
| 2023-05-09 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 135 | 9.51 | 1.3K | 77,447 | — | ↗ |
| 2023-04-11 | Levy Elliott M. | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 6.71 | 335.5K | 50,000 | — | ↗ |
| 2023-03-03 | ROBERTSON MICHELLE | Officer | S-Sale | D | Common Stock | 184 | 8.89 | 1.6K | 107,559 | — | ↗ |
| 2023-03-03 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 101 | 8.89 | 897.89 | 77,582 | — | ↗ |
| 2023-03-02 | ROBERTSON MICHELLE | Officer | A-Award | A | Common Stock | 31,500 | 0.00 | — | 107,743 | — | ↗ |
| 2023-03-02 | O'Neill Gilmore Neil | Director / Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 8.72 | 1.31M | 150,000 | — | ↗ |
| 2023-03-02 | Mei Baisong | Officer | A-Award | A | Stock Option (right to buy) | 54,000 | 8.72 | 470.9K | 54,000 | — | ↗ |
| 2023-03-02 | Eaton Bruce | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 8.72 | 436.0K | 50,000 | — | ↗ |
| 2023-02-13 | Shearman Mark S | Officer | S-Sale | D | Common Stock | 2,790 | 9.67 | 27.0K | 65,559 | — | ↗ |
| 2023-02-13 | ROBERTSON MICHELLE | Officer | S-Sale | D | Common Stock | 4,287 | 9.67 | 41.4K | 76,243 | — | ↗ |
| 2023-02-13 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 3,307 | 9.67 | 32.0K | 60,983 | — | ↗ |
| 2023-02-07 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 346 | 11.10 | 3.8K | 64,290 | — | ↗ |
| 2023-01-10 | ROBERTSON MICHELLE | Director / Officer | S-Sale | D | Common Stock | 1,752 | 8.16 | 14.3K | 80,530 | — | ↗ |
| 2022-12-05 | ROBERTSON MICHELLE | Director / Officer | S-Sale | D | Common Stock | 193 | 10.23 | 2.0K | 82,282 | — | ↗ |
| 2022-12-05 | Eaton Bruce | Director / Officer | S-Sale | D | Common Stock | 102 | 10.23 | 1.0K | 64,636 | — | ↗ |
| 2022-11-08 | Eaton Bruce | Director / Officer | S-Sale | D | Common Stock | 289 | 11.02 | 3.2K | 64,738 | — | ↗ |
| 2022-09-06 | ROBERTSON MICHELLE | Director / Officer | S-Sale | D | Common Stock | 192 | 15.01 | 2.9K | 82,475 | — | ↗ |
| 2022-09-06 | Eaton Bruce | Director / Officer | S-Sale | D | Common Stock | 101 | 15.01 | 1.5K | 65,027 | — | ↗ |
| 2022-08-09 | Eaton Bruce | Director / Officer | S-Sale | D | Common Stock | 293 | 18.60 | 5.4K | 65,128 | — | ↗ |
| 2022-07-18 | Mei Baisong | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-15 | Shearman Mark S | Director / Officer | S-Sale | D | Common Stock | 5,145 | 10.06 | 51.7K | 68,349 | — | ↗ |
| 2022-06-09 | Vaishnaw Akshay | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-09 | Scadden David | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-09 | Reeve Emma | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-09 | Hopfield Jessica | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-09 | Hirsch Andrew | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-09 | Connaughton Bernadette | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-09 | Chatterjee Meeta | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-03 | ROBERTSON MICHELLE | Director / Officer | S-Sale | D | Common Stock | 1,527 | 11.54 | 17.6K | 82,667 | — | ↗ |
| 2022-06-03 | Eaton Bruce | Director / Officer | S-Sale | D | Common Stock | 1,123 | 11.54 | 13.0K | 65,421 | — | ↗ |
| 2022-06-02 | O'Neill Gilmore Neil | Director | A-Award | A | Stock Option (right to buy) | 950,209 | 0.00 | — | 950,209 | — | ↗ |
| 2022-06-01 | O'Neill Gilmore Neil | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-05-09 | Eaton Bruce | Director / Officer | S-Sale | D | Common Stock | 297 | 13.11 | 3.9K | 66,544 | — | ↗ |
| 2022-04-14 | MULLEN JAMES C | Director | A-Award | A | Stock Option (right to buy) | 170,989 | 0.00 | — | 170,989 | — | ↗ |
| 2022-04-01 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 1,258 | 19.64 | 24.7K | 66,841 | — | ↗ |
| 2022-03-03 | ROBERTSON MICHELLE | Director / Officer | S-Sale | D | Common Stock | 767 | 17.33 | 13.3K | 84,194 | — | ↗ |
| 2022-03-03 | Eaton Bruce | Director / Officer | S-Sale | D | Common Stock | 403 | 17.33 | 7.0K | 68,386 | — | ↗ |
| 2022-02-10 | Shearman Mark S | Officer | A-Award | A | Stock Option (right to buy) | 93,398 | 17.29 | 1.61M | 93,398 | — | ↗ |
| 2022-02-10 | ROBERTSON MICHELLE | Officer | A-Award | A | Stock Option (right to buy) | 157,580 | 17.29 | 2.72M | 157,580 | — | ↗ |
| 2022-02-10 | Eaton Bruce | Officer | A-Award | A | Stock Option (right to buy) | 110,732 | 17.29 | 1.91M | 110,732 | — | ↗ |
| 2022-02-08 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 302 | 17.63 | 5.3K | 31,196 | — | ↗ |
| 2022-01-11 | ROBERTSON MICHELLE | Officer | S-Sale | D | Common Stock | 1,744 | 25.70 | 44.8K | 31,462 | — | ↗ |
| 2022-01-03 | MULLEN JAMES C | Director / Officer | S-Sale | D | Common Stock | 18,252 | 26.95 | 492.0K | 75,898 | — | ↗ |
| 2021-12-22 | Shearman Mark S | Officer | A-Award | A | Common Stock | 9,084 | 0.00 | — | 41,785 | — | ↗ |
| 2021-12-22 | ROBERTSON MICHELLE | Officer | A-Award | A | Common Stock | 4,471 | 0.00 | — | 33,206 | — | ↗ |
| 2021-12-22 | Michaels Lisa Anne | Officer | A-Award | A | Common Stock | 4,243 | 0.00 | — | 22,675 | — | ↗ |
| 2021-12-22 | MULLEN JAMES C | Director / Officer | A-Award | A | Common Stock | 36,477 | 0.00 | — | 94,150 | — | ↗ |
| 2021-12-22 | Eaton Bruce | Officer | A-Award | A | Common Stock | 3,472 | 0.00 | — | 31,498 | — | ↗ |
| 2021-11-12 | Michaels Lisa Anne | Officer | S-Sale | D | Common Stock | 1,568 | 38.33 | 60.1K | 18,432 | — | ↗ |
| 2021-11-09 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 287 | 40.61 | 11.7K | 28,026 | — | ↗ |
| 2021-10-26 | Connaughton Bernadette | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-18 | MULLEN JAMES C | Director / Officer | S-Sale | D | Common Stock | 13,805 | 38.03 | 525.0K | 57,673 | — | ↗ |
| 2021-09-30 | MULLEN JAMES C | Director / Officer | A-Award | A | Common Stock | 36,478 | 0.00 | — | 71,478 | — | ↗ |
| 2021-09-03 | Reeve Emma | Director | A-Award | A | Stock Option (right to buy) | 13,736 | 68.25 | 937.5K | 13,736 | — | ↗ |
| 2021-08-09 | ROBERTSON MICHELLE | Officer | M-Exempt | D | Stock Option (right to buy) | 2,500 | 30.65 | 76.6K | 115,000 | — | ↗ |
| 2021-08-09 | Eaton Bruce | Officer | S-Sale | D | Common Stock | 287 | 57.17 | 16.4K | 68,099 | — | ↗ |
| 2021-07-23 | Eaton Bruce | Officer | — | D | Stock Option (right to buy) | 110,000 | 33.98 | 3.74M | 0 | — | ↗ |
| 2021-06-28 | ROBERTSON MICHELLE | Officer | M-Exempt | D | Stock Option (right to buy) | 2,500 | 30.65 | 76.6K | 117,500 | — | ↗ |
| 2021-06-14 | Shearman Mark S | Officer | A-Award | A | Stock Option (right to buy) | 52,718 | 38.53 | 2.03M | 52,718 | — | ↗ |
| 2021-06-14 | MULLEN JAMES C | Director / Officer | A-Award | A | Stock Option (right to buy) | 170,989 | 45.69 | 7.81M | 170,989 | — | ↗ |
| 2021-06-03 | Vaishnaw Akshay | Director | A-Award | A | Stock Option (right to buy) | 11,538 | 33.36 | 384.9K | 11,538 | — | ↗ |
| 2021-06-03 | Scadden David | Director | A-Award | A | Stock Option (right to buy) | 11,538 | 33.36 | 384.9K | 11,538 | — | ↗ |
| 2021-06-03 | Hopfield Jessica | Director | A-Award | A | Stock Option (right to buy) | 11,538 | 33.36 | 384.9K | 11,538 | — | ↗ |
| 2021-06-03 | Hirsch Andrew | Director | A-Award | A | Stock Option (right to buy) | 11,538 | 33.36 | 384.9K | 11,538 | — | ↗ |
| 2021-06-03 | Chatterjee Meeta | Director | A-Award | A | Stock Option (right to buy) | 11,538 | 33.36 | 384.9K | 11,538 | — | ↗ |
| 2021-03-03 | Hopfield Jessica | Director | P-Purchase | A | Common Stock | 5,800 | 45.51 | 264.0K | 22,700 | — | ↗ |
| 2021-03-02 | ROBERTSON MICHELLE | Officer | A-Award | A | Common Stock | 10,303 | 0.00 | — | 28,735 | — | ↗ |
| 2021-03-02 | MULLEN JAMES C | Director / Officer | A-Award | A | Stock Option (right to buy) | 196,637 | 45.69 | 8.98M | 196,637 | — | ↗ |
| 2021-02-09 | Collins Cynthia | Officer | S-Sale | D | Common Stock | 1,262 | 66.65 | 84.1K | 43,760 | — | ↗ |
| 2021-01-12 | ROBERTSON MICHELLE | Officer | S-Sale | D | Common Stock | 1,568 | 78.27 | 122.7K | 18,432 | — | ↗ |
| 2020-12-17 | Chatterjee Meeta | Director | A-Award | A | Stock Option (right to buy) | 23,076 | 62.71 | 1.45M | 23,076 | — | ↗ |
| 2020-12-15 | Albright Charles | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 16.51 | 165.1K | 145,000 | — | ↗ |
| 2020-12-09 | Albright Charles | Officer | M-Exempt | A | Common Stock | 10,000 | 16.51 | 165.1K | 34,907 | — | ↗ |
| 2020-12-07 | Albright Charles | Officer | M-Exempt | A | Common Stock | 20,000 | 16.51 | 330.2K | 44,907 | — | ↗ |
| 2020-11-09 | Michaels Lisa Anne | Officer | A-Award | A | Stock Option (right to buy) | 120,000 | 30.41 | 3.65M | 120,000 | — | ↗ |
| 2020-11-09 | Albright Charles | Officer | S-Sale | D | Common Stock | 228 | 31.21 | 7.1K | 24,907 | — | ↗ |
| 2020-10-15 | Albright Charles | Officer | S-Sale | D | Common Stock | 3,000 | 31.39 | 94.2K | 25,135 | — | ↗ |
| 2020-08-20 | Collins Cynthia | Director / Officer | S-Sale | D | Common Stock | 1,976 | 36.66 | 72.4K | 45,022 | — | ↗ |
| 2020-08-17 | Albright Charles | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 16.51 | 165.1K | 185,000 | — | ↗ |
| 2020-08-07 | Albright Charles | Officer | S-Sale | D | Common Stock | 238 | 34.99 | 8.3K | 28,135 | — | ↗ |
| 2020-08-06 | Albright Charles | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 16.51 | 165.1K | 195,000 | — | ↗ |
| 2020-07-15 | Albright Charles | Officer | S-Sale | D | Common Stock | 3,000 | 32.22 | 96.7K | 28,373 | — | ↗ |
| 2020-06-10 | Vaishnaw Akshay | Director | A-Award | A | Stock Option (right to buy) | 11,538 | 27.49 | 317.2K | 11,538 | — | ↗ |
| 2020-06-10 | Scadden David | Director | A-Award | A | Stock Option (right to buy) | 11,538 | 27.49 | 317.2K | 11,538 | — | ↗ |
| 2020-06-10 | MULLEN JAMES C | Director | A-Award | A | Stock Option (right to buy) | 11,538 | 27.49 | 317.2K | 11,538 | — | ↗ |
| 2020-06-10 | Hopfield Jessica | Director | A-Award | A | Stock Option (right to buy) | 11,538 | 27.49 | 317.2K | 11,538 | — | ↗ |
| 2020-06-10 | Hirsch Andrew | Director | A-Award | A | Stock Option (right to buy) | 11,538 | 27.49 | 317.2K | 11,538 | — | ↗ |
| 2020-05-06 | Albright Charles | Officer | S-Sale | D | Common Stock | 151 | 25.28 | 3.8K | 31,373 | — | ↗ |
| 2020-02-07 | Albright Charles | Officer | S-Sale | D | Common Stock | 622 | 26.95 | 16.8K | 31,524 | — | ↗ |
| 2020-02-06 | Collins Cynthia | Director / Officer | A-Award | A | Stock Option (right to buy) | 93,750 | 28.05 | 2.63M | 93,750 | — | ↗ |
| 2020-02-06 | Albright Charles | Officer | A-Award | A | Stock Option (right to buy) | 69,556 | 28.05 | 1.95M | 69,556 | — | ↗ |
| 2020-02-03 | Albright Charles | Officer | S-Sale | D | Common Stock | 5,549 | 26.54 | 147.3K | 20,553 | — | ↗ |
| 2020-01-31 | Albright Charles | Officer | M-Exempt | A | Common Stock | 17,977 | 0.00 | — | 26,102 | — | ↗ |
| 2020-01-09 | ROBERTSON MICHELLE | Officer | A-Award | A | Stock Option (right to buy) | 120,000 | 30.65 | 3.68M | 120,000 | — | ↗ |
| 2019-10-28 | Abrams Judith R | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 21.61 | 3.24M | 150,000 | — | ↗ |
| 2019-09-11 | Collins Cynthia | Director / Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 26.57 | 6.64M | 250,000 | — | ↗ |
| 2019-08-19 | Collins Cynthia | Director / Officer | A-Award | A | Common Stock | 8,283 | 0.00 | — | 16,566 | — | ↗ |
| 2019-08-06 | Collins Cynthia | Director / Officer | A-Award | A | Common Stock | 8,283 | 0.00 | — | 16,566 | — | ↗ |
| 2019-06-12 | Vaishnaw Akshay | Director | A-Award | A | Stock Option (right to buy) | 11,538 | 21.74 | 250.8K | 11,538 | — | ↗ |
| 2019-06-12 | MULLEN JAMES C | Director | A-Award | A | Stock Option (right to buy) | 11,538 | 21.74 | 250.8K | 11,538 | — | ↗ |
| 2019-06-12 | Hopfield Jessica | Director | A-Award | A | Stock Option (right to buy) | 11,538 | 21.74 | 250.8K | 11,538 | — | ↗ |
| 2019-06-12 | Hirsch Andrew | Director | A-Award | A | Stock Option (right to buy) | 11,538 | 21.74 | 250.8K | 11,538 | — | ↗ |
| 2019-06-12 | Collins Cynthia | Director / Officer | A-Award | A | Stock Option (right to buy) | 11,538 | 21.74 | 250.8K | 11,538 | — | ↗ |
| 2019-03-18 | Myer Vickesh | Officer | S-Sale | D | Common Stock | 3,000 | 24.50 | 73.5K | 0 | — | ↗ |
| 2019-03-05 | Hopfield Jessica | Director | P-Purchase | A | Common Stock | 10,200 | 23.94 | 244.2K | 16,900 | — | ↗ |
| 2019-03-01 | Ek Eric | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-02-20 | Myer Vickesh | Officer | M-Exempt | D | Stock Option (right to buy) | 3,000 | 0.65 | 2.0K | 76,307 | — | ↗ |
| 2019-02-06 | Myer Vickesh | Officer | A-Award | A | Stock Option (right to buy) | 48,750 | 21.10 | 1.03M | 48,750 | — | ↗ |
| 2019-02-06 | Albright Charles | Officer | A-Award | A | Stock Option (right to buy) | 48,750 | 21.10 | 1.03M | 48,750 | — | ↗ |
| 2019-02-05 | Scadden David | Director | A-Award | A | Stock Option (right to buy) | 23,076 | 21.14 | 487.8K | 23,076 | — | ↗ |
| 2019-02-04 | Hack Andrew A. F. | Officer | M-Exempt | D | Stock Option (right to buy) | 6,895 | 6.48 | 44.7K | 9,618 | — | ↗ |
| 2019-01-31 | Myer Vickesh | Officer | A-Award | A | Restricted Stock Units | 16,722 | 0.00 | — | 16,722 | — | ↗ |
| 2019-01-31 | Collins Cynthia | Director | A-Award | A | Restricted Stock Units | 8,283 | 0.00 | — | 8,283 | — | ↗ |
| 2019-01-31 | Albright Charles | Officer | A-Award | A | Restricted Stock Units | 17,977 | 0.00 | — | 17,977 | — | ↗ |
| 2019-01-18 | Myer Vickesh | Officer | M-Exempt | D | Stock Option (right to buy) | 4,000 | 11.21 | 44.8K | 52,897 | — | ↗ |
| 2019-01-17 | Myer Vickesh | Officer | M-Exempt | D | Stock Option (right to buy) | 3,000 | 0.65 | 2.0K | 79,307 | — | ↗ |
| 2019-01-08 | Bosley Katrine | Director / Officer | S-Sale | D | Common Stock | 12,000 | 25.27 | 303.2K | 1,204,966 | — | ↗ |
| 2019-01-04 | Hack Andrew A. F. | Officer | M-Exempt | A | Common Stock | 7,000 | 6.48 | 45.4K | 7,000 | — | ↗ |
| 2018-12-18 | Myer Vickesh | Officer | M-Exempt | D | Stock Option (right to buy) | 4,000 | 11.21 | 44.8K | 56,897 | — | ↗ |
| 2018-12-17 | Myer Vickesh | Officer | M-Exempt | D | Stock Option (right to buy) | 3,000 | 0.65 | 2.0K | 82,307 | — | ↗ |
| 2018-12-06 | Collins Cynthia | Director | A-Award | A | Stock Option (right to buy) | 23,076 | 29.69 | 685.1K | 23,076 | — | ↗ |
| 2018-12-03 | Bosley Katrine | Director / Officer | S-Sale | D | Common Stock | 100 | 32.39 | 3.2K | 1,216,966 | — | ↗ |
| 2018-11-23 | Hack Andrew A. F. | Officer | S-Sale | D | Common Stock | 100 | 28.61 | 2.9K | 0 | — | ↗ |
| 2018-11-20 | Myer Vickesh | Officer | M-Exempt | D | Stock Option (right to buy) | 4,000 | 11.21 | 44.8K | 60,897 | — | ↗ |
| 2018-11-19 | Myer Vickesh | Officer | S-Sale | D | Common Stock | 2,700 | 28.12 | 75.9K | 0 | — | ↗ |
| 2018-11-01 | Bosley Katrine | Director / Officer | S-Sale | D | Common Stock | 3,400 | 26.03 | 88.5K | 1,237,566 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-17.7K
Shares Outstanding
97.91M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Gilmore O’Neill, M.B., M.M.Sc. President and Chief Executive Officer | 686.6K | — | — | 1.28M | 375.2K | 9.0K | 2.35M | 54.51% | ↗ |
| 2 | 2025 | Linda C. Burkly, Ph.D. Executive Vice President and Chief Scientific Officer | 517.2K | — | — | 441.4K | 207.0K | 10.8K | 1.18M | 37.52% | ↗ |
| 3 | 2025 | Amy Parison Senior Vice President and Chief Financial Officer | 394.2K | — | — | 266.1K | 154.0K | 7.3K | 821.7K | 32.39% | ↗ |
| 4 | 2024 | Gilmore O’Neill, M.B., M.M.Sc. President and Chief Executive Officer | 667.1K | — | 1.30M | 2.71M | 440.3K | 8.9K | 5.13M | 78.23% | ↗ |
| 5 | 2024 | Erick Lucera Former Executive Vice President and Chief Financial Officer | 482.6K | — | 350.2K | 733.7K | 234.5K | 8.3K | 1.81M | 59.91% | ↗ |
| 6 | 2024 | Baisong Mei, M.D., Ph.D. Former Executive Vice President and Chief Medical Officer | 492.3K | — | 75.3K | 1.8K | 243.0K | 8.9K | 821.4K | 9.40% | ↗ |
| 7 | 2023 | Gilmore O’Neill, M.B., M.M.Sc. President and Chief Executive Officer | 641.1K | — | 436.0K | 915.4K | 392.5K | 7.3K | 2.39M | 56.49% | ↗ |
| 8 | 2023 | Erick Lucera Former Executive Vice President and Chief Financial Officer | 285.6K | — | 748.6K | 1.03M | 146.1K | 794.00 | 2.22M | 80.48% | ↗ |
| 9 | 2023 | Erick Lucera Executive Vice President and Chief Financial Officer | 285.6K | — | 748.6K | 1.03M | 146.1K | 794.00 | 2.22M | 80.48% | ↗ |
| 10 | 2023 | Michelle Robertson Former Executive Vice President and Chief Financial Officer | 303.5K | — | 274.7K | 823.8K | — | 175.6K | 1.58M | 69.63% | ↗ |
| 11 | 2023 | Linda C. Burkly, Ph.D. Executive Vice President and Chief Scientific Officer | 209.4K | — | 391.1K | 815.7K | 113.2K | 7.6K | 1.54M | 78.52% | ↗ |
| 12 | 2023 | Bruce Eaton, Ph.D. Former Executive Vice President and Chief Business Officer | 469.2K | — | 145.6K | 396.9K | 214.7K | 79.0K | 1.31M | 41.56% | ↗ |
| 13 | 2023 | Baisong Mei, M.D., Ph.D. Senior Vice President and Chief Medical Officer | 459.9K | — | 157.0K | 329.5K | 187.0K | 8.0K | 1.14M | 42.62% | ↗ |
| 14 | 2023 | Baisong Mei, M.D., Ph.D. Former Executive Vice President and Chief Medical Officer | 459.9K | — | 157.0K | 329.5K | 187.0K | 8.0K | 1.14M | 42.62% | ↗ |
| 15 | 2022 | Gilmore O’Neill, M.B., M.M.Sc. President and Chief Executive Officer | 355.8K | — | 1,000.0K | 7.50M | 201.3K | 6.7K | 9.06M | 93.78% | ↗ |
| 16 | 2022 | Michelle Robertson Former Executive Vice President and Chief Financial Officer | 450.9K | — | 925.0K | 1.85M | 189.5K | 7.3K | 3.42M | 81.07% | ↗ |
| 17 | 2022 | Michelle Robertson Executive Vice President and Chief Financial Officer | 450.9K | — | 925.0K | 1.85M | 189.5K | 7.3K | 3.42M | 81.07% | ↗ |
| 18 | 2022 | Baisong Mei, M.D., Ph.D. Senior Vice President and Chief Medical Officer | 199.0K | 100.0K | 875.0K | 1.75M | 84.2K | 3.7K | 3.01M | 87.15% | ↗ |
| 19 | 2022 | Bruce Eaton, Ph.D. Former Executive Vice President and Chief Business Officer | 449.0K | 140.0K | 650.0K | 1.30M | 189.3K | 8.0K | 2.74M | 71.26% | ↗ |
| 20 | 2022 | Bruce Eaton, Ph.D. Executive Vice President and Chief Business Officer | 449.0K | 140.0K | 650.0K | 1.30M | 189.3K | 8.0K | 2.74M | 71.26% | ↗ |
| 21 | 2022 | Mark Shearman, Ph.D. Former Executive Vice President and Chief Scientific Officer | 492.8K | — | 548.2K | 1.10M | 207.8K | 8.0K | 2.35M | 69.89% | ↗ |
| 22 | 2022 | James Mullen Executive Chair; Former President and Chief Executive Officer | 654.4K | — | — | — | 361.6K | 35.0K | 1.05M | 0.00% | ↗ |
| 23 | 2021 | James Mullen President and Chief Executive Officer | 540.9K | — | — | 5.78M | 361.6K | 32.0K | 6.71M | 86.08% | ↗ |
| 24 | 2021 | James Mullen Executive Chair; Former President and Chief Executive Officer | 540.9K | — | — | 5.78M | 361.6K | 32.0K | 6.71M | 86.08% | ↗ |
| 25 | 2021 | Mark Shearman, Ph.D. Executive Vice President and Chief Scientific Officer | 253.1K | 247.5K | 1.61M | 1.30M | 133.9K | 5.4K | 3.55M | 81.97% | ↗ |
| 26 | 2021 | Mark Shearman, Ph.D. Former Executive Vice President and Chief Scientific Officer | 253.1K | 247.5K | 1.61M | 1.30M | 133.9K | 5.4K | 3.55M | 81.97% | ↗ |
| 27 | 2021 | Michelle Robertson Former Executive Vice President and Chief Financial Officer | 415.8K | — | 627.4K | 977.9K | 218.7K | 7.3K | 2.25M | 71.44% | ↗ |
| 28 | 2021 | Michelle Robertson Executive Vice President and Chief Financial Officer | 415.8K | — | 627.4K | 977.9K | 218.7K | 7.3K | 2.25M | 71.44% | ↗ |
| 29 | 2021 | Bruce Eaton, Ph.D. Executive Vice President and Chief Business Officer | 386.6K | — | 717.6K | 520.4K | 209.0K | 7.3K | 1.84M | 67.25% | ↗ |
| 30 | 2021 | Bruce Eaton, Ph.D. Former Executive Vice President and Chief Business Officer | 386.6K | — | 717.6K | 520.4K | 209.0K | 7.3K | 1.84M | 67.25% | ↗ |
| 31 | 2021 | Lisa Michaels, M.D. Former Executive Vice President and Chief Medical Officer | 470.0K | — | 148.7K | — | 196.7K | 7.3K | 822.6K | 18.07% | ↗ |
| 32 | 2021 | Cynthia Collins Former President and Chief Executive Officer | 86.5K | — | — | — | — | 575.9K | 662.4K | 0.00% | ↗ |
| 33 | 2020 | Michelle Robertson Executive Vice President and Chief Financial Officer | 387.7K | 140.0K | 613.0K | 2.37M | 112.9K | 6.7K | 3.63M | 82.19% | ↗ |
| 34 | 2020 | Michelle Robertson Chief Financial Officer | 387.7K | 140.0K | 613.0K | 2.37M | 112.9K | 6.7K | 3.63M | 82.19% | ↗ |
| 35 | 2020 | Lisa Michaels, M.D. Former Executive Vice President and Chief Medical Officer | 63.3K | 150.0K | 608.2K | 2.35M | — | 198.00 | 3.17M | 93.26% | ↗ |
| 36 | 2020 | Lisa Michaels, M.D. Executive Vice President and Chief Medical Officer | 63.3K | 150.0K | 608.2K | 2.35M | — | 198.00 | 3.17M | 93.26% | ↗ |
| 37 | 2020 | Cynthia Collins Former President and Chief Executive Officer | 620.2K | — | 438.3K | 1.68M | 264.6K | 108.2K | 3.12M | 68.13% | ↗ |
| 38 | 2020 | Charles Albright Ph.D. Former Executive Vice President and Chief Scientific Officer | 466.4K | — | 325.2K | 1.25M | — | 8.1K | 2.05M | 76.85% | ↗ |
| 39 | 2020 | Judith Abrams, M.D. Former Chief Medical Officer | 147.2K | — | — | — | — | 156.8K | 304.0K | 0.00% | ↗ |
| 40 | 2020 | Eric Ek Former interim Chief Financial Officer | 104.9K | — | — | — | — | — | 104.9K | 0.00% | ↗ |
| 41 | 2019 | Cynthia Collins Former President and Chief Executive Officer | 909.2K | — | 915.4K | 12.44M | 143.2K | 85.4K | 14.49M | 92.15% | ↗ |
| 42 | 2019 | Cynthia Collins President and Chief Executive Officer | 909.2K | — | 915.4K | 12.44M | 143.2K | 85.4K | 14.49M | 92.15% | ↗ |
| 43 | 2019 | Judith Abrams, M.D. Former Chief Medical Officer | 79.2K | 100.0K | 540.3K | 2.10M | — | 4.6K | 2.83M | 93.49% | ↗ |
| 44 | 2019 | Judith Abrams, M.D. Chief Medical Officer | 79.2K | 100.0K | 540.3K | 2.10M | — | 4.6K | 2.83M | 93.49% | ↗ |
| 45 | 2019 | Charles Albright Ph.D. Former Executive Vice President and Chief Scientific Officer | 427.8K | — | 562.1K | 701.5K | 297.0K | 8.1K | 2.00M | 63.29% | ↗ |
| 46 | 2019 | Charles Albright Ph.D. Executive Vice President and Chief Scientific Officer | 427.8K | — | 562.1K | 701.5K | 297.0K | 8.1K | 2.00M | 63.29% | ↗ |
| 47 | 2019 | Vic Myer, Ph.D. Former Chief Technology Officer | 287.9K | — | 534.8K | 701.5K | — | 84.6K | 1.61M | 76.85% | ↗ |
| 48 | 2019 | Eric Ek Former interim Chief Financial Officer | 1.14M | — | — | — | — | — | 1.14M | 0.00% | ↗ |
| 49 | 2019 | Katrine S. Bosley Former President and Chief Executive Officer | 655.5K | — | — | — | — | 5.8K | 661.2K | 0.00% | ↗ |
| 50 | 2019 | Andrew A. F. Hack, M.D., Ph.D. Former Chief Financial Officer | 64.1K | — | — | — | — | 6.1K | 70.2K | 0.00% | ↗ |
| 51 | 2018 | Katrine S. Bosley Former President and Chief Executive Officer | 560.0K | — | — | 7.14M | 261.8K | 30.6K | 7.99M | 89.33% | ↗ |
| 52 | 2018 | Andrew A. F. Hack, M.D., Ph.D. Former Chief Financial Officer | 375.8K | — | — | 2.47M | 127.8K | 30.5K | 3.00M | 82.20% | ↗ |
| 53 | 2018 | Vic Myer, Ph.D. Former Chief Technology Officer | 363.4K | — | — | 1.95M | 123.5K | 22.4K | 2.46M | 79.26% | ↗ |
| 54 | 2018 | Vic Myer, Ph.D. Chief Technology Officer | 363.4K | — | — | 1.95M | 123.5K | 22.4K | 2.46M | 79.26% | ↗ |
| 55 | 2018 | Charles Albright Ph.D. Executive Vice President and Chief Scientific Officer | 390.7K | — | — | 1.86M | 132.8K | 8.8K | 2.39M | 77.71% | ↗ |
| 56 | 2018 | Charles Albright Ph.D. Former Executive Vice President and Chief Scientific Officer | 390.7K | — | — | 1.86M | 132.8K | 8.8K | 2.39M | 77.71% | ↗ |
| 57 | 2018 | Charles Albright, Ph.D. Chief Scientific Officer | 390.7K | — | — | 1.86M | 132.8K | 8.8K | 2.39M | 77.71% | ↗ |
| 58 | 2018 | Gerald Cox, M.D. Former Chief Medical Officer | 408.0K | — | — | 1.56M | 138.7K | 28.6K | 2.13M | 73.02% | ↗ |
| 59 | 2017 | Katrine S. Bosley Former President and Chief Executive Officer | 520.0K | — | — | 5.31M | 257.4K | 6.5K | 6.09M | 87.13% | ↗ |
| 60 | 2017 | Katrine S. Bosley President and Chief Executive Officer | 520.0K | — | — | 5.31M | 257.4K | 6.5K | 6.09M | 87.13% | ↗ |
| 61 | 2017 | Andrew A. F. Hack, M.D., Ph.D. Former Chief Financial Officer | 346.2K | — | — | 1.57M | 125.4K | 6.4K | 2.05M | 76.70% | ↗ |
| 62 | 2017 | Andrew A. F. Hack, M.D., Ph.D. Chief Financial Officer | 346.2K | — | — | 1.57M | 125.4K | 6.4K | 2.05M | 76.70% | ↗ |
| 63 | 2017 | Charles Albright Ph.D. Executive Vice President and Chief Scientific Officer | 379.3K | — | — | 765.5K | 113.5K | 8.3K | 1.27M | 60.44% | ↗ |
| 64 | 2017 | Charles Albright, Ph.D. Chief Scientific Officer | 379.3K | — | — | 765.5K | 113.5K | 8.3K | 1.27M | 60.44% | ↗ |
| 65 | 2017 | Gerald Cox, M.D. Former Chief Medical Officer | 400.0K | — | — | — | 107.1K | 9.5K | 516.6K | 0.00% | ↗ |
| 66 | 2016 | Charles Albright, Ph.D. Chief Scientific Officer | 136.5K | — | — | 2.51M | 44.3K | 537.00 | 2.69M | 93.25% | ↗ |
| 67 | 2016 | Gerald Cox, M.D. Former Chief Medical Officer | 100.0K | — | — | 2.37M | — | — | 2.47M | 95.95% | ↗ |
| 68 | 2016 | Gerald Cox, M.D., Ph.D. Chief Medical Officer | 100.0K | — | — | 2.37M | — | — | 2.47M | 95.95% | ↗ |
| 69 | 2016 | Katrine S. Bosley Former President and Chief Executive Officer | 450.0K | — | — | 429.2K | 222.8K | 451.00 | 1.10M | 38.93% | ↗ |
| 70 | 2016 | Katrine S. Bosley President and Chief Executive Officer | 450.0K | — | — | 429.2K | 222.8K | 451.00 | 1.10M | 38.93% | ↗ |
| 71 | 2015 | Katrine S. Bosley President and Chief Executive Officer | 386.2K | — | — | — | 121.7K | — | 507.9K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gilmore O'Neill | President, Chief Executive Officer & Director | 1M | — |
| Linda C. Burkly | Executive Vice President & Chief Scientific Officer | 735.0K | — |
| Amy Parison | Senior Vice President & Chief Financial Officer | 555.5K | female |
| Damien Grierson | Senior Vice President, General Counsel & Corporate Secretary | — | male |
| Feng Zhang | Co-Founder & Scientific Advisory Board Member | — | — |
| Frank Panaccio | Senior Vice President & Chief Business Officer | — | male |
| George McDonald Church | Co-Founder & Scientific Advisory Board Member | — | — |
| Gregory Whitehead | Executive Vice President and Chief Technical & Quality Officer | — | male |
| Tom Love | Vice President of People | — | male |
| Brieana Buckley | Senior Vice President of Development and Program Leadership | — | female |
| Cristi Barnett | Senior Vice President of Corporate Communications & Investor Relations | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2023-04-10 | 2023-05-19 | Daniel Goldman | NY10 | — | Sale | $1,001 - $15,000 | ↗ |
| 2021-04-14 | 2021-05-01 | Donald Sternoff Beyer | VA08 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2021-03-02 | 2021-04-01 | Donald Sternoff Beyer | VA08 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2020-11-17 | 2020-12-01 | Donald Sternoff Beyer | VA08 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2020-05-01 | 2020-05-31 | Donald Sternoff Beyer | VA08 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2020-04-27 | 2020-05-09 | Donald Sternoff Beyer | VA08 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2020-01-27 | 2020-02-22 | Donald Sternoff Beyer | VA08 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2020-01-09 | 2020-02-22 | Donald Sternoff Beyer | VA08 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2019-12-23 | 2020-01-02 | Donald Sternoff Beyer | VA08 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2019-06-04 | 2020-04-27 | Donna Shalala | FL27 | -- | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2019-03-06 | 2020-04-27 | Donna Shalala | FL27 | -- | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EDIT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
